Skip to main content
PLOS One logoLink to PLOS One
. 2021 Mar 17;16(3):e0238898. doi: 10.1371/journal.pone.0238898

Molecular epidemiology of Mycobacterium tuberculosis complex in the Volta Region of Ghana

Selassie Ameke 1,2, Prince Asare 1, Samuel Yaw Aboagye 1, Isaac Darko Otchere 1, Stephen Osei-Wusu 1, Dorothy Yeboah-Manu 1,2, Adwoa Asante-Poku 1,2,*
Editor: Igor Mokrousov3
PMCID: PMC7968653  PMID: 33730036

Abstract

Context

Available molecular epidemiological data from recent studies suggest significant genetic variation between the different lineages of Mycobacterium tuberculosis complex (MTBC) and the MTBC lineages might have adapted to different human populations.

Aim

This study sought to determine the population structure of clinical MTBC isolates from the Volta Region of Ghana.

Methods

The MTBC isolates obtained from collected sputum samples were identified by PCR detecting of IS6110 and genotyped using spoligotyping. Non-tuberculous mycobacterial isolates were characterized by amplification of the heat shock protein 65 (hsp65) gene and sequencing. The drug susceptibility profiles of the MTBCs determined using GenoType MTBDRplus.

Results

One hundred and seventeen (117, 93.6%) out of 125 mycobacterial positive isolates were characterized as members of the MTBC of which M. tuberculosis sensu stricto (MTBss) and M. africanum (MAF) were respectively 94 (80.3%) and 23 (19.7%). In all, 39 distinct spoligotype patterns were obtained; 26 for MTBss and 13 for MAF lineages. Spoligotyping identified 89 (76%) Lineage 4, 16 (13.6%) Lineage 5, 7 (6.0%) Lineage 6, 3 (2.6%) Lineage 2, 1(0.9%) Lineage 3 and 1 (0.9%) Lineage 1. Among the Lineage 4 isolates, 62/89 (69.7%) belonged to Cameroon sub-lineage, 13 (14.7%) Ghana, 8 (9.0%) Haarlem, 2 (2.2%) LAM, 1 (1.1%) Uganda I, 1 (1.1%) X and the remaining two (2.2%) were orphan. Significant localization of MAF was found within the Ho municipality (n = 13, 29.5%) compared to the more cosmopolitan Ketu-South/Aflao (n = 3, 8.3%) (p-value = 0.017). Eight (8) non-tuberculous mycobacteria were characterized as M. abscessus (7) and M. fortuitum (1).

Conclusion

We confirmed the importance of M. africanum lineages as a cause of TB in the Volta region of Ghana.

Introduction

Tuberculosis (TB) still remains an important global public health problem and continues to pose great burden on the healthcare systems of many developing countries especially in Sub-Saharan Africa [1]. Due to the worldwide emergence of multidrug-resistant TB strains and the increasing burden of HIV, TB is gradually becoming untreatable. In 2019, an estimated 10 million people contracted TB with 1.3 million TB-related deaths placing TB among the top ten causes of death worldwide [1]. In Ghana, TB still poses a public health challenge with a TB incidence rate of 148/100,000 population per year, is ranked the 19th most TB-burdened country in Africa by WHO [1]. In 2017, Ghana together with Angola, Democratic Republic of Congo, Ethiopia, Kenya, Uganda and South Africa, constituted high TB-HIV burden countries in Africa [1].

Mycobacterium tuberculosis sensu stricto (MTBss) and Mycobacterium africanum (MAF) are the major pathogenic species of the M. tuberculosis complex (MTBC) in humans [2, 3]. There are 8 lineages of the MTBC, Lineages 1 to 4,7 and 8 belonging to MTBss whereas L5 and L6 belonging to MAF. Improved genomic analysis disproves previous dogma of genomic homogeneity of these lineages but indicates that there are significant variation with functional implications. We now also know that these lineages exhibit a phylogeographical structure with specific lineages being associated with distinct geographical areas [4] suggesting potential host-pathogen interaction. This could influence the broad applicability of control tools such as diagnostics and vaccine [4].

M. africanum (MAF) is endemic only in West Africa causing up to 40% of TB in some West African settings. MAF is considered less virulent compared to other human TB causing pathogens [5, 6] thus, expected to be outcompeted by the more virulent MTBss over time [5]. However, findings from recent studies still indicate significant presence of MAF within West Africa [68]. One reason for the high prevalence of MAF might be due to the stable adaptation of this lineage to some human populations. Two independent molecular epidemiological studies from our group, found a strong association between MAF and an indigenous West African ethnic group (Ewe ethnicity) which was driven by MAF L5 [9, 10]. A follow up comparative genomics studies, found MAF lineages (L5 and L6) to be completely different pathogens [2]. The genome of MAF L5 indicated a pathogen of limited host range compared to L6, which gave an indication of wide host range [11]. The Volta region is the traditional home of the Ewe ethnicity in Ghana; however, relative to the other regions of the country, to the best of our knowledge no study on the population structure of prevailing strains have been done [8, 12]. We characterized MTBC isolates obtained from patients attending specific health facility in the Volta region of Ghana to determine the circulating genotypes and drug resistance.

Subjects and methods

Study design, ethical clearance and case recruitment

This was a one-year cross-sectional study. All protocols used for this study were reviewed and approved by the Institutional Review Board of the Noguchi Memorial Institute for Medical Research with federal assurance number FWA00001824. Written informed consent was sought from all participants but for minors under 18 years, consent was sought from their parents or legal guardians. The objectives of the study and procedures were explained carefully to all study participants before inclusion into the study. The procedure for sputum sample collection for routine diagnosis of TB in Ghana was followed. A structured questionnaire was used to obtain standard demographic and epidemiologic data of patients. Two hundred and seventy (270) consented newly diagnosed smear-positive pulmonary TB patients agreed to be included in the study. Collected samples were stored at 4°C and transported within 4 days to Noguchi Memorial Institute for Medical Research (NMIMR) for laboratory analysis.

Study area and patients’ characteristics

The study was conducted in 12 public health facilities located in the Volta Region of Ghana which together reports more than 90% of all TB cases in Volta Region as indicated in Fig 1. Approximately 70% of the inhabitants of the study area are of the Ewe ethnicity [13] with main occupation being crop and fish farmers along the Volta Lake.

Fig 1. Study location and 12 health facilities selected.

Fig 1

ADH: Akatsi District Hospital, AGH: Adidome Government Hospital, CCH: Comboni Catholic Hospital, HoMH: Ho Municipal Hospital, Hohoe-MH: Hohoe Municipal Hospital, Keta-MH: Keta Municipal Hospital, Ketu-SMH: Ketu South Municipal Hospital, MMCH: Margret Marquardt Catholic Hospital, VRH: Volta Regional Hospital, STH: South Tongu Hospital, THC: Tsito Health Center, PGH: Peki Government Hospital.

Isolation of mycobacterial species from sputa

Sputum samples were decontaminated using the 5% oxalic acid decontamination method and inoculated on 4 Lowenstein–Jensen (L-J) media (2 L-J media supplemented with glycerol and 2 with pyruvate) and incubated at 37°C until macroscopic growth was observed as previously described [14]. Direct smear microscopy was performed for confirmation of acid-fast bacilli (AFB) using Ziehl-Neelsen (ZN) staining.

Isolation of genomic DNA

A loop full of mycobacterial colonies confirmed as AFB growing at the log phase was suspended in 1mL of sterile distilled water and inactivated by heating at 95°C for 1 hour to disrupt mycobacterial cell wall to release DNA into suspension. The resulting suspension was stored at -20°C and used for all downstream DNA-based assays.

Genotyping of MTBC

Mycobacteria isolates were confirmed as members of the MTBC by PCR amplification of the MTBC-specific insertion sequence 6110 (IS6110). All IS6110 positive samples were genotyped by spoligotyping as previously described using primers DRa (5’-CCG AGA GGG GAC GGA AAC-3’) and biotinylated DRb (5’-GGT TTT GGG TCT GAC GAC-3’) [15]. In Brief, the amplified DNA was tested for the presence of specific spacers by hybridization with a set of 43 oligonucleotides derived from the spacer sequences of M. tuberculosis H37Rv and M. bovis BCG P3 (the GenBank accession no. for the sequence of M. tuberculosis H37Rv is Z48304, and that for M. bovis BCG P3 is X57835). Bound fragments were revealed by chemiluminescence after incubation with horseradish peroxidase-labeled streptavidin (Boehringer Mannheim). Negative water controls were PCR amplified and included on each blot to identify any possible amplicon contamination. In addition, positive controls (H37Rv and M. bovis BCG DNA) was amplified and included on each blot. Shared types were defined as patterns common to at least two or more isolates. All patterns that could not be assigned were considered orphan spoligotypes. Spoligotypes were analysed as character types. The obtained spoligotyping patterns were compared with those available in the international spoligotype database SITVIT and SpolDB4 databases containing 35,925 spoligotypes comprising 39,295 isolates from 122 countries. A shared type was defined as a spoligotyping pattern common to at least two isolates, and clades were assigned according to signatures described in the database. Relationships among the isolates were inferred from Spoligotyping using the both SITVIT and SpolDB4 databases. All IS6110-negative isolates were further characterized by PCR amplification and sequencing of the mycobacterial specific heat shock protein (hsp) 65 with the primers TB11: 5’-ACC AAC GAT GGT GTG TCC AT-3’ and TB12: 5’-CTT GTC GAA CCG CAT ACC CT- 3’as previously described [15, 16].

Drug susceptibility testing by line probe assay

Confirmed MTBC isolates were screened for their susceptibility to isoniazid (INH) and rifampicin (RIF) using the GenoType MTBDRplus version 2.0 (Hain Lifesciences) according to the manufacturer’s protocol (Hain Lifesciences, 2015). Drug resistance was expressed as the absence of wild-type band, presence of mutation band or both.

Data analysis

Information from the structured questionnaire was entered into Microsoft excel and validated. Statistical analyses such as Chi-square and fisher’s exact test were carried out using STATA SE 12 with p-values of less than 0.05 at 95% confidence considered significant. Spoligotype patterns were entered in a binary format in Microsoft excel, uploaded and compared with those available in the online database http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE and http://www.miru-vntrplus.org useful in molecular typing of Mycobacterium tuberculosis complex. The genetic relationships among all of the identified circulating spoligotype patterns were studied by constructing a dendrogram using the categorical parameter and the UPGMA coefficient available in the miru-vntrplus online tool (SpolDB4).

Results

Study population

From January 2016 to January 2017, 270 participants were enrolled into the study. One hundred and eighty-three were confirmed as acid-fast bacilli positive (67.8%), of which 125 isolates were obtained from culture (68%). Of the 125 isolates obtained, 8 (6.4%) were identified as non-tuberculous mycobacteria whereas 2 (1.6%) could not be typed after repeated analysis and were thus excluded from further analysis. Hence, a total of 115 MTBC isolates were used for the downstream analysis. As indicated in Table 1, age of patients ranged from 12 to 86 years with a mean age of 44.8 years ± 14.9 years. Thirty-five (30.4%) of the cases were females and the remaining 80 (70.1%) being males. Majority of the participants 107 (93.0%) were mainly of the Ewe ethnicity. The main occupation were, traders 44/115 (38.31%) and farmers 35/115 (30.4%). All 115 TB patients consented to HIV testing, and sero-positivity was 3.5%.

Table 1. Characteristics of MTBC positive participants.

Gender (115) Value (percentage)
Male 80 (69.6)
Female 35 (30.4)
Age (115)
Mean ± SD 44.8 ± 14.9 years
Median (IQR) 43 (35–54) years
Occupation (115)
Traders 42 (36.5)
Farmer 34 (29.6)
Artisans 9 (7.8)
Drivers 5 (4.3)
Students 4 (3.5)
Teacher 2 (1.7)
Hospital Orderlies 1 (0.9)
Unemployed 15 (13.0)
Religion (115)
Christianity 107 (93.0)
Islam 4 (3.5)
Traditional 2 (1.7)
No Religion 2 (1.7)
Ethnicity (115)
Ewe 107 (93.0)
Guan 3 (2.6)
Hausa 3 (2.6)
Akan 1 (0.9)
Fulani 1 (0.9)
Nationality (115)
Ghanaians 112 (97.4)
Togolese 2 (1.7)
Malian 1 (0.9)
HIV Status (115)
Negative 93 (80.9)
Positive 4 (3.5)
Not Done 18 (15.6)
Previously Treated (115)
No 111 (96.5)
Yes 4 (3.5)

Population structure of the MTBC isolates

Based on spoligotyping, we identified six out of the seven human-associated MTBC lineages in our study population (Table 2). Lineage distributions are 89 (76%) Lineage 4, 16 (13.6%) Lineage 5, 7 (6.0%) Lineage 6, 3 (2.6%) Lineage 2, 1 (0.9%) Lineage 3 and 1 (0.9%) Lineage 1. Among the Lineage 4 isolates, 62/89 (69.7%) belonged to Cameroon sub-lineage, 13 (14.7%) Ghana, 8 (9.0%) Haarlem, 2 (2.2%) LAM, 1 (1.1%) Uganda I, 1 (1.1%) X and the remaining two (2.2%) were orphan. Among the 89 L4, 62/89 (69.7%) belonged to the Cameroon sub-lineage (mostly the spoligotype with shared international type (SIT) number 61). In addition to the Cameroon family, four other sub-lineages namely 13 (14.7%) Ghana, 8 (9.0%) Haarlem, 1 (1.1%) Uganda I, 2 (2.2%) LAM, 1 (1.1%) X and the remaining two (2.2%) were orphan (Table 2). Overall, we identified 39 distinct spoligotyping patterns among the 117 MTBC isolates analysed. Twenty-one unique patterns (singletons) and 18 clustered patterns comprising of 96 isolates were also identified. The odds of an isolate belonging to a cluster were higher among MTBss compared to MAF (OR = 4.39 CI = 1.56–12.35). Cameroon sub-lineage of MTBss strain gave the largest cluster with 44 isolates sharing a spoligotype (SIT 61). In addition, we identified 23 novel spoligotypes among our isolates compared to the SITVIT database (Fig 2).

Table 2. Prevalence of Mycobacterium tuberculosis complex lineages and sub-lineages.

Species (N = 115) Lineages Sub-Lineages Number (%)
MTBss (91, 79.1%) Lineage 2 Beijing 3 (2.6%)
Lineage 3 Delhi/CAS 1 (0.9%)
Lineage 4 (87, 75.7%) Cameroon 64 (55.6%)
Ghana 11 (9.6%)
Haarlem 9 (7.8%)
LAM 2 (1.7%)
X 1 (0.9%)
MAF (24, 20.9%) Lineage 5 West Africa I 17 (14.8%)
Lineage 6 West Africa II 7 (6.1%)

Fig 2. Relationship of identified 33 spoligotype profiles.

Fig 2

Tree was plotted using the MIRU-VNTRplus web application available at https://www.miru-vntrplus.org/.

Spatial distribution of MTBC lineages and sub-lineages among MTBC Isolates

The combined number of isolates analysed from the different geographical areas, together with identified species, lineages and sub-lineages are indicated in Fig 3. As expected MTBss dominated in all sites, and was the only lineage identified in Hohoe(n = 14), Sogakofe(n = 3) and Kpando (n = 1). We found significant difference in inter-municipality comparisons. For instance, driven by Lineage 5, the proportions of MAF in Ho Municipality, 13/44 (29.6%) showed a significantly higher proportion (p-value = 0.017) than in Ketu-South Municipality (Aflao), 3/36 (8.3%) (Fig 3).

Fig 3. Geospatial distribution of the two human adapted MTBC species; M. tuberculosis sensu stricto (MTBss) and M. africanum (MAF).

Fig 3

Figure was generated in ArcGIS. Permissions: The authors permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Prevalence of drug resistance among the MTBC isolates

A total of 101 MTBC isolates were analyzed by GenoType® MTBDRplus version 2.0 following the manufacturer’s instructions. We found 6 (5.9%), 5 (4.9%) and 2 (1.9%) of the isolates to be INH mono-resistant, RIF mono-resistant and multidrug resistant (MDR) respectively (Table 3) Stratifying our dataset by genotypes, five (6.41%) of the MTBss isolates were found to be INH mono-resistant while only one (4.55%) MAF isolate was resistant to INH. All the RIF-mono resistant and the two MDR isolates were found to be MTBss. All two MDR isolates showed the MUT3 band for rpoB gene which corresponds to the SNP C1592U that resulted in the locus amino acid change, S531L. One of the MDR isolates in addition to the above had the MUT2B band which is associated with the locus amino acid change, H526D. None of the RIF-mono resistant isolates showed a mutation band but rather absence of wild-type bands. Majority of the RIF-mono resistant isolates had the rpoB wild-type band, WT1 absent, and its absence is associated with any of these loci amino acid changes, F505L, T508A or S509T. Similarly, an absence of rpoB wild-type band WT8 in three isolates corresponds with any of these loci amino acid changes, S531L, S531W or L533P. The isoniazid resistance among the MDRs was conferred by KatG mutant MUT1 that corresponds to the SNP U943A that resulted in the S315T locus amino acid change. The KatG mutation dominated in 4 MTBss isolates and was responsible for majority of INH resistance. However, inhA mutants MUT1 and MUT3B associated with the locus amino acid changes C15T, and T8A on the promoter region were also implicated in INH resistance as shown in Table 3.

Table 3. Drug susceptibility profile of the human adapted MTBC isolates amongst TB patients.

INH RIF MDR
Species Sensitive Resistant OR (CI) p-value Sensitive Resistant OR (CI) p-value
MTBss (N = 75) 67 (89.3%) 8 (10.7%) 2.75 (0.33–127.06) 0.3350 68 (90.7%) 7 (9.3%) 2.37 (028–111.27) 0.4189 3 (4.0%)
MAF (N = 24) 23 (95.8%) 1 (4.2%) 23 (95.8%) 1 (4.2%) 0 (0%)
Total (N = 99 93 (93.9%) 6 (6.1%) 94 (94.9%) 5 (5.1%) 3 (3.0%)

Identified nontuberculous mycobacteria species

The 8 AFB positive isolates that were IS6110 negative were identified by hsp65 gene sequencing followed by NCBI Blast search. Seven of them as M. abscessus and the remaining one as M. fortuitum.

Discussion

We sought to determine the population structure of MTBC isolates obtained from smear positive pulmonary patients attending public health facilities in the Volta Region. We found unique spatial distribution of 6 lineages of MTBC with MAF being responsible for 19.7% of cases, odds of (INH)-mono resistance, (RIF)-mono resistance and MDR higher for MTBss infection and identification of NTMs in 8 TB cases.

Previous studies in Ghana reported the prevalence of 6 human-adapted MTBC lineages in the Greater Accra, Central and the Northern regions of Ghana [10, 14]. In this study we found these 6 MTBC lineages also circulating in the Volta Region suggesting their establishment in Ghana. Comparing the proportion of MAF to the national prevalence of 20% we observed no significant difference (p-value = 0.951) indicating that the same proportion is circulating in the Volta Region [14]. Approximately 20% MAF proportion has been found in previous studies to be fairly stable over an 8-year period [8].

M. africanum is an important cause of human TB in West Africa, causing about 50% of all TB cases reported in some West African countries. Past epidemiological surveys saw a dramatic drop of MAF numbers in several West African countries [17, 18], suggesting a replacement by the more virulent MTBss. However in sharp contrast, two recent studies from several regions in Nigeria (Abuja, Ibadan, Nnewi and Cross River State) estimated persistently high MAF prevalence between 14% and 33% and detected foci of recent transmission [1921].

One possible reason for the stability of MAF in Ghana and West Africa irrespective of the observed lower virulence might be adaptation of this lineage to specific human populations. Recently, two independent molecular epidemiological studies conducted in Ghana found a strong association of MAF with the Ewe ethnicity [9, 10]. Since Volta region is the home of the Ewe ethnic group, we decided to assess the distribution of MAF within this region. Although we expected to find a greater proportion of MAF in the Volta region, more so when most of the participants were of Ewe ethnicity, interestingly we found significant difference in inter-municipality comparisons. For instance, driven by L5, the proportions of MAF in the Ewe dominated Ho Municipality, 13/44 (29.6%) showed a significantly higher proportion than in Ketu-South Municipality (Aflao), 3/36 (8.3%) (p-value = 0.017). The significantly lower prevalence of MAF in the Ketu-South Municipality may be due to the diverse human populations as a result of travelers and migrants present at every point in time crossing the border to and from the Republic of Togo. This observation of significant association of MAF with the Ewes could be an indication of a possible predisposing factor among this human population to MAF infection.

Drug resistance remains a great threat to the fight against TB. Using proportional method, Asante-Poku et al., (2015) (10) and Homolka et al., (2010) [12] recorded high INH mono resistance. Other studies have reported high level INH resistance (40–95%) to be associated with 75–90% katG position S315T mutation [22, 23]. Using Line probe assay, our study observed 40% high level INH resistance that was associated with only 57.14% katG position S315T mutation. Our finding was consistent with findings by Otchere et al., (2016) [11], which showed that the human adapted strain MTBss compared to MAF has a relatively greater risk of possessing this position S315T mutation in katG (p < 0.001). Riccardi et al., (2009) [24], associated RIF resistance with the rpoB gene mutations which cluster mainly in the codon region of 507–533. Although inconsistent with the mutation in rpoB S450L reported by Otchere et al. (2016) [11], our findings showed rpoB gene mutation distribution of 37.5% S531L and 12.5% H526D. The amino acid change from polar serine to non-polar leucine at position 531 and from basic histidine to aspartic acid at position 526 may have contributed to conformational change in protein structure. This may have subsequently prevented proper binding of the drug RIF to the β-subunit of the DNA dependent RNA polymerase leading to drug resistance.

Differential diagnosis of MTBCs and Non-tuberculous mycobacteria (NTMs) is very crucial for the appropriate treatment regimen to be administered [2527]. While the standard treatment regimen for MTBC infection takes 6 months, NTMs therapy however takes between 18–24 months with different drug regimen based on thorough drug susceptibility testing as the NTMs are naturally resistant to majority of anti-TB drugs [25]. In this study, NTMs were isolated from 6.4% of patients presumptively diagnosed with TB using the NTP diagnostic algorithm. This was higher than 2.5% observed by Otchere et al. [28], but consistent with studies by Bertoletti et al., (2011) [29]. The NTMs isolated, M. abscessus, and M. fortuitum are known to be fast growing mycobacteria that can cause pulmonary infections in both immunocompetent and immunocompromised individuals. Microscopy, which is used for TB diagnosis in the periphery medical laboratories, lacks specificity and is unable to distinguish between MTBCs and NTMs. These observations support the need to pay critical attention to differential diagnosis of pulmonary infectious mycobacteria, most especially in the rolling out of DNA-based diagnostics especially among cases that do not sputum convert after two months of anti-TB treatment to allow appropriate management of such cases.

In conclusion, our study confirms the importance of MAF in Ghana and highlight the need to incorporate MAF studies into development of TB control tools.

Acknowledgments

We express our gratitude to all laboratory staff and study participants of the various health facilities for their time and cooperation during the study period.

Data Availability

Data cannot be shared publicly because of patient confidentiality. Data are available from the Noguchi Memorial Institutional Data Access / Ethics Committee (contact via GWemakor@noguchi.ug.edu.gh) for researchers who meet the criteria for access to confidential data.

Funding Statement

This work was supported by WACCBIP Postdoctoral Fellowship funds to A.A.P from a DELTAS Africa grant (DEL-15-007: Awandare). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (107755/Z/15/Z: Awandare) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. SM was supported by Wellcome Trust intermediate fellowship grant 097134/Z/11/Z to Dorothy Yeboah-Manu.

References

  • 1.World Health Organization Global Tuberculosis Report. Geneva. 2019
  • 2.Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. U. S. A. 2002;99:3684–3689. 10.1073/pnas.052548299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Meyer CG, Scarisbrick G, Niemann S, Browne EN, Chinbuah MA, et al. Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection. Tuberculosis (Edinb). 2008; 88: 482–489. 10.1016/j.tube.2008.05.004 [DOI] [PubMed] [Google Scholar]
  • 4.Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 2007;7:328–337. 10.1016/S1473-3099(07)70108-1 [DOI] [PubMed] [Google Scholar]
  • 5.de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, Adetifa IM, et al. Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis. 2008;198(7):1037–43. 10.1086/591504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum—Review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis. 2010. 4; e744. 10.1371/journal.pntd.0000744 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gehre F, Antonio M, Faïhun F, Odoun M, Uwizeye C, de Rijk P, et al. The First Phylogeographic Population Structure and Analysis of Transmission Dynamics of M. africanum West African 1—Combining Molecular Data from Benin, Nigeria and Sierra Leone. PLOS ONE 8(10): e77000. 10.1371/journal.pone.0077000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yeboah-Manu D, Asare P, Asante-Poku A, Otchere ID, Osei-Wusu S, Danso E, et al. Spatio-Temporal Distribution of Mycobacterium tuberculosis Complex Strains in Ghana. PLoS ONE 2016;11(8): e0161892. 10.1371/journal.pone.0161892 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Asante-Poku A, Otchere ID, Osei-Wusu S, Sarpong E, Baddoo A, Forson A, et al. Molecular epidemiology of Mycobacterium africanum in Ghana. BMC Infect Dis 2016. 16, 385 10.1186/s12879-016-1725-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Asante-Poku A, Yeboah-Manu D, Otchere ID, Aboagye SY, Stucki D, Hattendorf J, et al. Mycobacterium africanum is associated with patient ethnicity in Ghana. PLoS Negl Trop Dis. 2015. January 8;9(1):e3370. 10.1371/journal.pntd.0003370 ; PMCID: PMC4287525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Otchere ID, Asante-Poku A, Osei-Wusu S, Baddoo A, Sarpong E, Ganiyu AH, et al. Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana. Tuberculosis (Edinburgh, Scotland). 2016; 99:147–154. 10.1016/j.tube.2016.05.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Homolka S, Meyer CG, Hilleman D, Owusu-Dabo E, Adjei O, Horstmann RD, et al. Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. Int J Med Microb. 2010; 300:489–495. 10.1016/j.ijmm.2010.04.019 [DOI] [PubMed] [Google Scholar]
  • 13.Government of Ghana: Ghana Demographic and Health Survey, Final Report. 2010
  • 14.Yeboah-Manu D, Asante-Poku A, Bodmer T, Stucki D, Koram K, Bonsu F, et al. Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One. 2011; 6(7): e21906. 10.1371/journal.pone.0021906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997; 35(4):907–14 10.1128/JCM.35.4.907-914.1997 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993;31(2):175–178. 10.1128/JCM.31.2.175-178.1993 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Groenheit R, Ghebremichael S, Svensson J, Rabna P, Colombatti R, Riccardi F, et al. The Guinea-Bissau family of Mycobacterium tuberculosis complex revisited. PLoS One. 2011; 6: e18601. 10.1371/journal.pone.0018601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ouassa T, Borroni E, Loukou GY, Faye-Kette H, Kouakou J, Menan K, et al. High prevalence of shared international type 53 among Mycobacterium tuberculosis complex strains in retreated patients from Cote d’Ivoire. PLoS One. 2012; 7: e45363. 10.1371/journal.pone.0045363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lawson L, Zhang J, Gomgnimbou MK, Abdurrahman ST, Le Moullec S, Mohammed F, et al. A molecular epidemiological and genetic diversity study of tuberculosis in Ibadan, Nnewi and Abuja, Nigeria. PLoS One 2012; 7: e38409. 10.1371/journal.pone.0038409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Thumamo BP, Asuquo AE, Abia-Bassey LN, Lawson L, Hill V, Zozio T, et al. Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria. Infect Genet Evol. 2012: 12: 671–677. 10.1016/j.meegid.2011.08.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Affolabi D, Anyo G, Faihun F, Sanoussi N, Shamputa IC, Rigout L, et al. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis 2009; 13: 317–322. [PubMed] [Google Scholar]
  • 22.Hazbón MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al. Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2006; 50 (8) 2640–2649 10.1128/AAC.00112-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Vilchèze C, Jacobs WR Jr. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr. 2014;2(4) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Riccardi G, Pasca MR. Trends in discovery of new drugs for tuberculosis therapy. The Journal of Antibiotics. 2014;67(1–5.) 10.1038/ja.2014.109 [DOI] [PubMed] [Google Scholar]
  • 25.Sinha P, Gupta A, Prakash P, Anupurba S, Tripathi R, Srivastava GN. Differentiation of Mycobacterium tuberculosis complex from non-tubercular mycobacteria by nested multiplex PCR targeting IS6110, MTP40 and 32kD alpha antigen encoding gene fragments. BMC Infect Dis. 2016; 16:123. 10.1186/s12879-016-1450-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sharma SK, Sharma R, Singh BK, Upadhyay V, Mani I, Tripathi M, et al. A prospective study of non-tuberculous mycobacterial disease among tuberculosis suspects at a tertiary care centre in north India. Indian J Med Res. 2019;150(5):458–467. 10.4103/ijmr.IJMR_194_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ryu YJ, Won-Jung K, Daley CL. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians’ Perspectives. Tuberc Respir Dis 2016;79:74–84 10.4046/trd.2016.79.2.74 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Otchere I, Asante-Poku A, Osei-Wusu S, Aboagye S, Yeboah-Manu D. Isolation and Characterization of Nontuberculous Mycobacteria from Patients with Pulmonary Tuberculosis in Ghana. International journal of mycobacteriology. 2017; 6(1):70–75. 10.4103/2212-5531.201895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bertoletti AC, Alves KJ, Chimara E, Aily DC. Isolation of mycobacteria from clinical samples in the Rio Claro region: Frequency analysis. Rev Inst Adolfo Lutz 2011;70:622–30. [Google Scholar]

Decision Letter 0

Igor Mokrousov

13 Nov 2020

PONE-D-20-26015

Molecular Epidemiology of Mycobacterium tuberculosis complex in Volta Region of Ghana

PLOS ONE

Dear Dr. Aasante-Poku,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

A major revision is required of all parts of the manuscript to improve presentation, data analysis and interpretation as recommended by the reviewers. In particular, do use the most recent SITVIT2 and not outdated SpolDb4.

Please submit your revised manuscript by Dec 28 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Igor Mokrousov, Ph.D., D.Sc.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for your title change from "phylogenetic..." to "molecular epidemiology..."

Please also revise the text of your manuscript to remove references to phylogenetics in the following places:

a) Key Message

b) Last paragraph of your Introduction

c) End of your Genotyping of MTBC section

d) Figure 2 legend

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Please include a copy of Table 5 which you refer to in your text on page 12.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors present important and timely findings which will add to the gaps in knowledge on the molecular epidemiology of TB in Africa and Ghana to be precise. The manuscript however, will require revising as recommended below:

-Ensure that formatting and grammar is checked throughout the entire document, there are several grammatical errors throughout the document, i.e. lines 37 and 44, no full stops after a sentence, line 73 two comas after Ethiopia, line 78 check spacing before and after 7.

-Abstract: Instead of the statement "standard methods" list the methods used during analysis refer to line 42. Decimal places should be consistent throughout the manuscript i.e. line 49 is presented as 76.04% instead of 76.06% which should be rounded to 76.1% to maintain one decimal place throughout the manuscript. Check that the calculations for percentages are correct, percentages are not adding up to 100%, refer to lines 49 and 50. List percentages for the two orphans. It will be useful to add Ghana and spoligotyping to the list of key words and either limit to tuberculosis and MAF in order to maintain the journal limit.

-Some statements will need to be rephrased in order for them to be more cohesive i.e. lines 68/69 rephrase the sentence beginning "The worldwide.." to "Due to the worldwide". Insert "TB"after multidrug-resistant in line 68. Rephrase line 71 to "...public health challenge; with a TB incidence rate of...". Check line 72 "a is ranked...". Line 74 insert "and" between Uganda and South Africa, delete "the" before Africa in line 74.

-Study design: line 136 should be changed from "on patients" to "of patients". Line 137, state how many samples were included, were all samples included? and how samples were selected for analysis. line 150, there shouldn't be a space between 37 and degree C. DRb and not "Drb"line 165. Spacing between bovis and BCG line 167. lines 171 to 174 "in order... each blot" are not necessary, authors can delete the statement and simply refer to the reference. Line 175 should make reference to the database use to assign SIT and orphans. line 178 refers to the SpolDB4, however the SITVIT2 is a more updated version of the SpolDB4 which the authors should use to compare their spoligo findings and make reference to. Authors should cite manufacturers correctly line 188.

-Data analysis: the titles data analysis and results (lines 192 and 201) are underlined which is not consistent with the remainder of the manuscript. Was SITVIT2 or SpolDB not used for analysis? line 197.

-Results: The sample size should also be mentioned earlier, somewhere in the study design i.e. line 137. Line 204, only 125 out of 270 (46%) positive isolates were characterised, why is this the case? This impacts on the conclusions drawn as it is not a good representation of isolates from this region, should be mentioned later as a limitation to the study. Delete "The" from the title in line 216. Was phenotypic DST data available? If so this should be included in table 1. Lines 218-219, lineage statistics don't add up to 100% and are not matching with the data presented in the abstract. Line 244 table number not indicated. Line 252 "wide type band" shouldn't be in italics.

-Discussion: line 278, refrain from listing i), ii)... Line 287 should read "Approximately..." and not "The approximately...". A full stop after ref (14) in line 287. Line 289, it is not advisable to start a sentence with an abbreviation "MAF". In your discussion and conclusion you will need to address the fact that only 46% of isolates collected over the study period were characterised and how this would impact on the data that you have presented. Line 310, delete "pulmonary" since drug resistant TB can impact treatment outcome EPTB as well as PTB. et al should be in italics throughout including in reference list. Abbreviate M. abscessus in line 333 unless this was the first use. Rephrase the statement "The challenge is, microscopy..."in line 335. There is a big jump from speaking about diagnostics to concluding on MAF genotype, you will need to add a few sentences that connect the previous statement with your conclusion line 341.

-References: Check the reference style is uniform throughout your reference list and conforms with the journal requirements, italicize "et al". Delete () in line 373

-Figures: Is figure 1 the authors own work? If not cite the source. Figure 2 percentages are not adding up to 100%.

Reviewer #2: It was interesting reading your manuscript even similars studies have been done in the country in the same subject except for the Volta Region which add a value to the manuscript. I noticed minor corrections regarding the form for several lines: you need to adjust the space between some words see line 37;44;73;78;99;167:204;207;228;235;244;273;313;319

Please make M.africanum in italic in all the manuscript for example line 62.

Also a coma must be place in line 260 after table 3 and in line 287 after the refererence 14.

some references are old like the TB report which date is 2018, new TB report are available please use it

References content some errors which need to be correct: references 2;4;6;9;10;12;16;25;29;30;31

Table 3 must be redone to improve understanding because it is rather poorly presented

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Namaunga Kasumu Chisompola

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 17;16(3):e0238898. doi: 10.1371/journal.pone.0238898.r002

Author response to Decision Letter 0


23 Dec 2020

editor

All comments has been addressed

Reviewer 1

all comments and edits have been addressed

Reviewer2

all comments and edits have been addressed

Attachment

Submitted filename: Response to reviewers.doc

Decision Letter 1

Igor Mokrousov

30 Dec 2020

PONE-D-20-26015R1

Molecular Epidemiology of Mycobacterium tuberculosis complex in Volta Region of Ghana

PLOS ONE

Dear Dr. Aasante-Poku,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Before consider the following changes before I can proceed with your manuscript:

1.Your Cover letter is presented in the format with visible track changes mode. Please submit a clean version of cover letter.

2. Your answers to the editor and reviewers provided in this way are not acceptable. 

"editor

All comments has been addressed

Reviewer 1

all comments and edits have been addressed

Reviewer2

all comments and edits have been addressed"

The answers should be detailed and point-to-point; it is also advised in each answer to refer to the particular page and line numbers in the revised version.

Please submit your revised manuscript by Feb 13 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Igor Mokrousov, Ph.D., D.Sc.

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 17;16(3):e0238898. doi: 10.1371/journal.pone.0238898.r004

Author response to Decision Letter 1


26 Feb 2021

Editor

1.Please ensure that that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Response: The Manuscript has been revised to meet PLOS ONE style requirement

2. Thank you for your title change from "phylogenetic..." to "molecular epidemiology..."

Please also revise the text of your manuscript to remove references to phylogenetics in the following places:

a) KeyMessage

b) Last paragraph of your Introduction

c) End of your Genotyping of MTBC section

d) Figure 2 legend

Response: The Manuscript text has been revised to remove references to “phylogenetic in the key areas suggested

3.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the inform

Response:The cover letter has been revised to reflect the ethical restrictions on the data set.

4. Please include a copy of Table 5 which you refer to in your text on page 12.

Response: Table 5 has been removed from the manuscript accordingly

Reviewers comment

Reveiwer 1

1.Ensure that formatting and grammar is checked throughout the entire document, there are several grammatical errors throughout the document, i.e. lines 37 and 44, no full stops after a sentence, line 73 two commas after Ethiopia, Line 78 check spacing before and after 7

Response: We thank the reviewer for the discovery of these errors.The grammatical errors throughout the document corrected accordingly

2. Abstract: Instead of the statement "standard methods" list the methods used during analysis refer to line 42.

Response:Standard methods haven clarified. Line 41-42

3. Decimal places should be consistent throughout the manuscript i.e. line 49 is presented as 76.04% instead of 76.06% which should be rounded to 76.1% to maintain one decimal place throughout the manuscript.

Response: Decimal places corrected throughout the manuscript to one decimal place. Line 49

4. Check that the calculations for percentages are correct, percentages are not adding up to 100%, refer to lines 49 and 50.

Response: All percentages corrected throughout the manuscript to one decimal place. Line 52

5. List percentages for the two orphans.

Response: Percentages of the two orphans listed. Line 52

6. It will be useful to add Ghana and spoligotyping to the list of key words and either limit to tuberculosis and MAF in order to maintain the journal limit.

Response: Ghana and spoligotyping added to the key words Line 58

7. Some statements will need to be rephrased in order for them to be more cohesive i.e.

lines 68/69 rephrase the sentence beginning "The worldwide." to "Due to the worldwide".

Response: The worldwide corrected Due to the worldwide" Line 70

8. Insert "TB"after multidrug-resistant in line 68.

Response: TB" inserted after multidrug-resistant. Line 70

9. Rephrase line 71 to "...public health challenge; with a TB incidence rate of...".

Response : Line 71 corrected to read: "with a TB incidence rate of". Line 73

10. Check line 72 "a is ranked...".

Response: "a" deleted Line 74

11. Line 74 insert "and" between Uganda and South Africa, delete "the" before Africa in line 74

Response: "and" inserted between Uganda and South Africa. Line 76

12. Study design: line 136 should be changed from "on patients" to "of patients". Line 137.

Response: line 136 changed from "on patients" to "of patient. Line 142

13. State how many samples were included, were all samples included? and how samples were selected for analysis.

Response: All samples collected were included in the study. Line 142

14. line 150, there shouldn't be a space between 37 and degree C.

Response: Space between 37 and degree C corrected. Line 155

15. DRb and not "Drb"line 165.

Response: "Drb" corrected to DrB. Line 174

16. Spacing between bovis and BCG line 167.

Response: Spacing between bovis and BCG corrected. Line 176

17. lines 171 to 174 "in order... each blot" are not necessary, authors can delete the statement and simply refer to the reference.

Response: Text in Lines 171 to 174 deleted

18. Line 175 should make reference to the database use to assign SIT and orphans. line 178 refers to the SpolDB4, however the SITVIT2 is a more updated version of the SpolDB4 which the authors should use to compare their spoligo findings and make reference to. Authors should cite manufacturers correctly line 188.

Response: Obtained spoligotyping patterns were compared with those available in the international spoligotype database SITVIT and SpolDB4 . Line 212

19. Data analysis: the titles data analysis and results (lines 192 and 201) are underlined which is not consistent with the remainder of the manuscript.

Response: We have duly undone the underlines. Line 207, 233

20. Was SITVIT2 or SpolDB not used for analysis? line 197.

Response: Both SITVIT2 and SpolDB were used for analysis. Lime 212

21. Results: The sample size should also be mentioned earlier, somewhere in the study design i.e. line 137.

Response: sample size indicated in the study design. Line 142

22. Line 204, only 125 out of 270 (46%) positive isolates were characterised, why is this the case? This impacts on the conclusions drawn as it is not a good representation of isolates from this region, should be mentioned later as a limitation to the study.

Response: Thank you very much for the comment. However, 270 participants were enrolled into the study. One hundred and eighty-three were confirmed as acid-fast bacilli positive (67.8%), of which 125 culture positives (68%) where obtained. The results has been corrected to reflect this statement.. Line 235-239

23. Delete "The" from the title in line 216.

Response: "The deleted from the Title. Line 249

24. Was phenotypic DST data available? If so this should be included in table 1.

Response: DST was performed for all isolates obtained. The results has been presented in a Table 3. Line 300

25. Lines 218-219, lineage statistics don't add up to 100% and are not matching with the data presented in the abstract.

Response: Percentages corrected to match the data presented in the abstract. Line 258

26. Line 244 table number not indicated.

Response:Table number indicated. Line 258

27. Line 252 "wide type band" shouldn't be in italics.

Response: "wild-type band" has been un- italised. Line 289

28. Discussion: line 278, refrain from listing i), ii)...

Response:Numbering of key results has been deleted. Line 311-314

30. Line 287 should read "Approximately..." and not "The approximately...".

Response: Text corrected accordingly. Line 325

31. A full stop after ref (14) in line 287.

Response: Full stop added accordingly. Line 320

32. Line 289, it is not advisable to start a sentence with an abbreviation "MAF".

Response:MAF written out in full. Line 293

33. In your discussion and conclusion you will need to address the fact that only 46% of isolates collected over the study period were characterised and how this would impact on the data that you have presented.

Response:Thank you very much for the comment. However, 270 participants were enrolled into the study. One hundred and eighty-three were confirmed as acid-fast bacilli positive (67.8%), of which 125 culture positives (68%) where obtained. The results has been corrected to reflect this statement. Line 248-250

34. Line 310, delete "pulmonary" since drug resistant TB can impact treatment outcome EPTB as well as PTB.

Response:As suggested by reviewer "pulmonary" deleted from the sentence/ Line 410

35. et al should be in italics throughout including in reference list.

Response: et al italised throughout the reference list

36. Abbreviate M. abscessus in line 333 unless this was the first use.

Response:Mycobacterium abscessus abbreviated to M. abscessus in text. Line 377

37. Rephrase the statement "The challenge is, microscopy..."in line 335.

Response:The sentence has been rephrased. Line 377

38. There is a big jump from speaking about diagnostics to concluding on MAF genotype, you will need to add a few sentences that connect the previous statement with your conclusion line 341.

Response: Thank you for your comments. A few Sentences has been added

39. References: Check the reference style is uniform throughout your reference list and conforms with the journal requirements, italicize "et al".

Response: Reference style corrected. Line 515

40.Delete () in line 373

Response: () deleted. Line 450

41. Figures: Is figure 1 the authors own work? If not cite the source.

Response:Thank you for the comment. Figure 1 is the authors own work

42.Figure 2 percentages are not adding up to 100%.

Response: Percentages corrected for Figure 2.

Reviewer 2

1.you need to adjust the space between some words see line 37;44;73;78;99;167:204;207;228;235;244;273;313;319

Response: Topographic errors have been corrected through out the manuscript

2. Please make M.africanum in italic in all the manuscript for example line 62.

Response:M.africanum has been italised through the manuscript. Line 62

3.Also a coma must be place in line 260 after table 3 and in line 287 after the refererence 14

Response:Thank you for the comment. A full stop has been placed in Line 266 after Table 3 and Line 287. Line 295, 320

4.some references are old like the TB report which date is 2018, new TB report are available please use it

Response: Thank you for the comment. Referece changed to reflect new TB report

5.References content some errors which need to be correct: references 2;4;6;9;10;12;16;25;29;30;31

Response:Reference content corrected

6.Table 3 must be redone to improve understanding because it is rather poorly presented

Response:Thank you for the comment. Table 3 has been redone. Line 300

Decision Letter 2

Igor Mokrousov

1 Mar 2021

Molecular Epidemiology of Mycobacterium tuberculosis complex in Volta Region of Ghana

PONE-D-20-26015R2

Dear Dr. Aasante-Poku,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Igor Mokrousov, Ph.D., D.Sc.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Igor Mokrousov

9 Mar 2021

PONE-D-20-26015R2

Molecular epidemiology of Mycobacterium tuberculosis complex in the Volta Region of Ghana

Dear Dr. Aasante-Poku:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Igor Mokrousov

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to reviewers.doc

    Data Availability Statement

    Data cannot be shared publicly because of patient confidentiality. Data are available from the Noguchi Memorial Institutional Data Access / Ethics Committee (contact via GWemakor@noguchi.ug.edu.gh) for researchers who meet the criteria for access to confidential data.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES